Wockhardt to exit its US generics business
Habil Korakiwala, Chairman, Wockhardt Group | Photo Credit: PAUL NORONHA Drugmaker Wockhardt is realigning its business in the US by focusing on its innovation-driven business,
Wockhardt to exit residual US generics business for “commercial reasons”
Drugmaker Wockhardt has decided to exit its remaining generics business in the US, for commercial reasons. Over two years ago, the Mumbai-based drugmaker had announced
Day 1 after diabetes drug Empagliflozin goes off patent, generics go to town with it
Drugmakers have begun to roll-out their generic versions of diabetes drug Empagliflozin – on day one after the innovative drug from Boehringer Ingelheim (BI) went
